Tags

Type your tag names separated by a space and hit enter

Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
Clin Neurol Neurosurg. 2006 Feb; 108(2):124-8.CN

Abstract

OBJECTIVES

Matrix metalloproteinases (MMPs), particularly MMP-9, facilitate T-cell migration into the central nervous system. They play a key role in the disruption of the blood-brain barrier (BBB) and thus in the pathogenesis of multiple sclerosis. Interferon beta's (IFNbeta) ability to alter the balance between MMP-9 and MMP-9s natural inhibitor, tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), may play a role in stabilizing the BBB. The aim of this study, was to evaluate serum MMP-9 and TIMP-1 and cerebrospinal fluid (CSF) TIMP-1 levels in patients with relapsing-remitting multiple sclerosis (RRMS) treated with IFNbeta-1a.

PATIENTS AND METHODS

Blood and CSF samples from 14 patients with RRMS before and 6 months after IFNbeta therapy and 14 age and sex-matched controls were obtained. Levels of MMP-9 and TIMP-1 were measured using ELISA.

RESULTS

Before treatment, patients with MS had higher levels of serum MMP-9 and a higher MMP-9/TIMP-1 ratio than the controls. Although serum levels of TIMP-1 were lower in RRMS patients than in the controls, the differences did not reach statistical significance. CSF levels of TIMP-1 were significantly lower in RRMS patients. In the sixth month of IFNbeta therapy serum MMP-9 and the MMP-9/TIMP-1 ratio were significantly decreased, whereas the changes in serum TIMP-1 were not statistically significant. There was a significant increase in CSF TIMP-1 levels in the sixth month of IFNbeta therapy.

CONCLUSIONS

Our result shows that RRMS patients have an impaired MMP-9 and TIMP-1 balance, and that 6 months of IFNbeta therapy is beneficial in restoring this balance.

Authors+Show Affiliations

Department of Neurology, Faculty of Medicine, Karadeniz Technical University, 61080 Trabzon, Turkey. cavitb@yahoo.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16412833

Citation

Boz, Cavit, et al. "Matrix Metalloproteinase-9 (MMP-9) and Tissue Inhibitor of Matrix Metalloproteinase (TIMP-1) in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon Beta." Clinical Neurology and Neurosurgery, vol. 108, no. 2, 2006, pp. 124-8.
Boz C, Ozmenoglu M, Velioglu S, et al. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta. Clin Neurol Neurosurg. 2006;108(2):124-8.
Boz, C., Ozmenoglu, M., Velioglu, S., Kilinc, K., Orem, A., Alioglu, Z., & Altunayoglu, V. (2006). Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta. Clinical Neurology and Neurosurgery, 108(2), 124-8.
Boz C, et al. Matrix Metalloproteinase-9 (MMP-9) and Tissue Inhibitor of Matrix Metalloproteinase (TIMP-1) in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon Beta. Clin Neurol Neurosurg. 2006;108(2):124-8. PubMed PMID: 16412833.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta. AU - Boz,Cavit, AU - Ozmenoglu,Mehmet, AU - Velioglu,Sibel, AU - Kilinc,Kagan, AU - Orem,Asim, AU - Alioglu,Zekeriya, AU - Altunayoglu,Vildan, PY - 2004/10/16/received PY - 2005/01/06/revised PY - 2005/01/24/accepted PY - 2006/1/18/pubmed PY - 2006/4/12/medline PY - 2006/1/18/entrez SP - 124 EP - 8 JF - Clinical neurology and neurosurgery JO - Clin Neurol Neurosurg VL - 108 IS - 2 N2 - OBJECTIVES: Matrix metalloproteinases (MMPs), particularly MMP-9, facilitate T-cell migration into the central nervous system. They play a key role in the disruption of the blood-brain barrier (BBB) and thus in the pathogenesis of multiple sclerosis. Interferon beta's (IFNbeta) ability to alter the balance between MMP-9 and MMP-9s natural inhibitor, tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), may play a role in stabilizing the BBB. The aim of this study, was to evaluate serum MMP-9 and TIMP-1 and cerebrospinal fluid (CSF) TIMP-1 levels in patients with relapsing-remitting multiple sclerosis (RRMS) treated with IFNbeta-1a. PATIENTS AND METHODS: Blood and CSF samples from 14 patients with RRMS before and 6 months after IFNbeta therapy and 14 age and sex-matched controls were obtained. Levels of MMP-9 and TIMP-1 were measured using ELISA. RESULTS: Before treatment, patients with MS had higher levels of serum MMP-9 and a higher MMP-9/TIMP-1 ratio than the controls. Although serum levels of TIMP-1 were lower in RRMS patients than in the controls, the differences did not reach statistical significance. CSF levels of TIMP-1 were significantly lower in RRMS patients. In the sixth month of IFNbeta therapy serum MMP-9 and the MMP-9/TIMP-1 ratio were significantly decreased, whereas the changes in serum TIMP-1 were not statistically significant. There was a significant increase in CSF TIMP-1 levels in the sixth month of IFNbeta therapy. CONCLUSIONS: Our result shows that RRMS patients have an impaired MMP-9 and TIMP-1 balance, and that 6 months of IFNbeta therapy is beneficial in restoring this balance. SN - 0303-8467 UR - https://www.unboundmedicine.com/medline/citation/16412833/Matrix_metalloproteinase_9__MMP_9__and_tissue_inhibitor_of_matrix_metalloproteinase__TIMP_1__in_patients_with_relapsing_remitting_multiple_sclerosis_treated_with_interferon_beta_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0303-8467(05)00025-9 DB - PRIME DP - Unbound Medicine ER -